Skip to content
The Policy VaultThe Policy Vault

bexarotene gelMedica

Adult T-cell leukemia/lymphoma (smoldering symptomatic subtype)

Initial criteria

  • Patient has smoldering symptomatic subtype
  • Medication is used as first-line therapy
  • Medication is prescribed by or in consultation with an oncologist or a dermatologist

Approval duration

1 year